Summary
The single- and repeated-dose pharmacokinetics of sabeluzole have been determined in six elderly patients with [senile] dementia of the Alzheimer type.
After a single oral dose of 10 mg sabeluzole, the peak plasma concentration was attained at 1 to 4 h; it averaged 42 ng·ml−1. On repeated dosing (10 mg b. d.), steady-state was virtually attained after 3 days of treatment. Steadystate mean trough and peak plasma concentrations fluctuated between 53 and 94 ng·ml−1. The mean terminal half-life after a single dose and at steady-state was of the order of 33 h.
Sabeluzole was well tolerated and at the end of treatment, no systematic changes in blood haematology, biochemistry or urinalysis were seen.
This is a preview of subscription content, log in via an institution to check access.
References
Wauquier A, Clincke G, Ashton D, De Ryck M, Fransen J, Van Clemen G (1986) R 58 735: Anew antihypoxic drug with anticonvulsant properties and possible effects on cognitive functions. Drug Dev Res 8: 373–380
Clincke G, Sahgal A (1986) R 58 735, a novel antihypoxic drug improves memory in rats. Drug Dev Res 8: 381–385
Pauwels PJ, Leysen JE and Janssen PAJ (1990) Resistance of sabeluzole-treated rat brain neuronal cultures to neuronal damage. Neurosci Res Corn 6: 19–26
Geerts H, Nuydens R, Nuyens R, Cornelissen F, De Brabander M, Pauwels P, Janssen PAJ, Song YH and Mandelkow EM (1992) Sabeluzole, a memory enhancing molecule increases fast axonal transport in neuronal cell cultures. Exp Neurol 117: 36–43
Clincke GHC, Tritsmans L, Idzikowski C, Amery WK, Janssen PAJ (1988) The effect of R 58 735 (Sabeluzole) on memory functions in healthy elderly volunteers. Psychopharmacol 94: 52–57
Clincke GHC, Tritsmans L (1988) Sabeluzole (R 58 735) increases consistent retrieval during serial learning and relearning of nonsense syllables. Psychopharmacol 96: 309–310
Tritsmans L, Clincke G, Amery WK (1988) The effect of sabeluzole (R 58 735) on memory retrieval functions. Psychopharmacol 94:527–531
Tritsmans L, Clincke G, Devenijns F, Verhoolsel G, Amery WK (1988) Memory study with sabeluzole in a population with a mean age of 85 years: a pilot experiment. Current Ther Res 44: 966–974
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939–944
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed, Dekker, New York
Van de Velde V, Van Peer A, Tritsmans L, Gasparini R, Woestenborghs R, Heykants J, Amery W (1986) Single and repeated dose pharmacokinetics of R 58 735 in healthy volunteers. Pharmaceutisch Weekblad (Scientific Edition) 8: 311
Van Peer A, Tritsmans L, Gasparini R, Woestenborghs R, Lorreyne W, Heykants J, Amery W (1986) Multiple dose pharmacokinetics of R 58 735 10 mg b. i. d. in healthy volunteers. Clinical Research Report R58735/3, Janssen Research Foundation, Beerse, Belgium
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Deyn, P.P., Van de Velde, V., Verslegers, W. et al. Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients. Eur J Clin Pharmacol 43, 661–662 (1992). https://doi.org/10.1007/BF02284969
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02284969